Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Imunon, Inc.IMNN · Entity 8041 | Director · Executive Chairman of Board | October 09, 2026 | October 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Imunon, Inc.
Report date October 09, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 111,721 |
Reported balance
After 2026-10-09 transaction · row 1
1 source rowRow 1 · 2026-10-09 · Grant · Acquired 7,800 · Balance 111,721 F1: Stock granted in lieu of cash for base salary |
| Common StockSEC Table I · non-derivative | IndirectHeld by IRA | 4,622 |
Reported balance
Holding disclosure · report date 2026-10-09 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 4,622 |
Filing footnotes · ownership attribution and instrument terms
F1: Stock granted in lieu of cash for base salary
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 09, 2026 Filed Oct 13, 2026 20:08 UTC | Imunon, Inc. IMNN · Entity 8041 | GrantCommon Stock | 7,800 | $1.08 | $8,424.00 |
DisclosureSEC source: 0001437749-26-032563 · rdgdoc.xml · nonDerivative · entry 1 Tardugno Michael H · CIK 0001384550 · Director · Executive Chairman of Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,721 F1 · shares: Stock granted in lieu of cash for base salary Read SEC document |
| September 25, 2026 Filed Sep 28, 2026 20:31 UTC | Imunon, Inc. IMNN · Entity 8041 | GrantCommon Stock | 7,169 | $1.41 | $10,108.29 |
DisclosureSEC source: 0001437749-26-031363 · rdgdoc.xml · nonDerivative · entry 1 Tardugno Michael H · CIK 0001384550 · Director · Executive Chairman of Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,921 F1 · shares: Stock granted in lieu of cash for base salary Read SEC document |
| September 11, 2026 Filed Sep 15, 2026 16:43 UTC | Imunon, Inc. IMNN · Entity 8041 | GrantCommon Stock | 5,824 | $1.47 | $8,561.28 |
DisclosureSEC source: 0001437749-26-030415 · rdgdoc.xml · nonDerivative · entry 1 Tardugno Michael H · CIK 0001384550 · Director · Executive Chairman of Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,699 F1 · shares: Stock granted in lieu of cash for base salary Read SEC document |
| August 28, 2026 Filed Sep 1, 2026 20:10 UTC | Imunon, Inc. IMNN · Entity 8041 | GrantCommon Stock | 7,371 | $1.60 | $11,793.60 |
DisclosureSEC source: 0001437749-26-029409 · rdgdoc.xml · nonDerivative · entry 1 Tardugno Michael H · CIK 0001384550 · Director · Executive Chairman of Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,875 F1 · shares: Stock granted in lieu of cash for base salary Read SEC document |
| August 14, 2026 Filed Aug 17, 2026 20:21 UTC | Imunon, Inc. IMNN · Entity 8041 | GrantCommon Stock | 7,147 | $1.65 | $11,792.55 |
DisclosureSEC source: 0001437749-26-028185 · rdgdoc.xml · nonDerivative · entry 1 Tardugno Michael H · CIK 0001384550 · Director · Executive Chairman of Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,504 F1 · shares: Stock granted in lieu of cash for base salary Read SEC document |
| July 31, 2026 Filed Aug 4, 2026 20:12 UTC | Imunon, Inc. IMNN · Entity 8041 | GrantCommon Stock | 6,358 | $1.59 | $10,109.22 |
DisclosureSEC source: 0001437749-26-025660 · rdgdoc.xml · nonDerivative · entry 1 Tardugno Michael H · CIK 0001384550 · Director · Executive Chairman of Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,357 F1 · shares: Stock granted in lieu of cash for base salary Read SEC document |
| July 17, 2026 Filed Jul 21, 2026 20:17 UTC | Imunon, Inc. IMNN · Entity 8041 | GrantCommon Stock | 4,603 | $1.83 | $8,423.49 |
DisclosureSEC source: 0001437749-26-023949 · rdgdoc.xml · nonDerivative · entry 1 Tardugno Michael H · CIK 0001384550 · Director · Executive Chairman of Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,999 F1 · shares: Stock granted in lieu of cash for base salary Read SEC document |
| July 02, 2026 Filed Jul 7, 2026 21:05 UTC | Imunon, Inc. IMNN · Entity 8041 | GrantCommon Stock | 4,410 | $1.91 | $8,423.10 |
DisclosureSEC source: 0001437749-26-022948 · rdgdoc.xml · nonDerivative · entry 1 Tardugno Michael H · CIK 0001384550 · Director · Executive Chairman of Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,396 F1 · shares: Stock granted in lieu of cash for base salary Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 20:22 UTC | Imunon, Inc. IMNN · Entity 8041 | GrantCommon Stock | 42,519 | $1.72 | $73,132.68 |
DisclosureSEC source: 0001437749-26-022003 · rdgdoc.xml · nonDerivative · entry 1 Tardugno Michael H · CIK 0001384550 · Director · Executive Chairman of Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,986 F1 · shares: Stock granted in lieu of cash for 50% of 2025 annual cash bonus Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 23:59 UTC | Imunon, Inc. IMNN · Entity 8041 | GrantCommon Stock | 4,629 | $1.82 | $8,424.78 |
DisclosureSEC source: 0001437749-26-021484 · rdgdoc.xml · nonDerivative · entry 1 Tardugno Michael H · CIK 0001384550 · Director · Executive Chairman of Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,467 F1 · shares: Stock granted in lieu of cash for base salary Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 21:15 UTC | Imunon, Inc. IMNN · Entity 8041 | GrantCommon Stock | 4,089 | $2.06 | $8,423.34 |
DisclosureSEC source: 0001437749-26-020037 · rdgdoc.xml · nonDerivative · entry 1 Tardugno Michael H · CIK 0001384550 · Director · Executive Chairman of Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,838 F1 · shares: Stock granted in lieu of cash for base salary Read SEC document |
| May 22, 2026 Filed May 27, 2026 20:22 UTC | Imunon, Inc. IMNN · Entity 8041 | GrantCommon Stock | 3,484 | $2.20 | $7,664.80 |
DisclosureSEC source: 0001437749-26-018566 · rdgdoc.xml · nonDerivative · entry 1 Tardugno Michael H · CIK 0001384550 · Director · Executive Chairman of Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,749 F1 · shares: Stock granted in lieu of cash for base salary Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:05 UTC | Imunon, Inc. IMNN · Entity 8041 | GrantStock Option (Right to Buy) · Derivative | 43,821 | $0.00 Strike: $3.95 | $0.00 |
DisclosureSEC source: 0001437749-26-000605 · rdgdoc.xml · derivative · entry 1 Tardugno Michael H · CIK 0001384550 · Director · Executive Chairman of Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,821 Underlying: Common Stock · 43,821 shares Expires 2036-01-02 F1 · derivative.exercise_price: Represents the closing price of Imunon, Inc. Common Stock on the date of the grant F2 · derivative.exercise_date: The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant. Read SEC document |
| August 04, 2025 Filed Aug 6, 2025 20:23 UTC | Imunon, Inc. IMNN · Entity 8041 | GrantStock Option (Right to Buy) · Derivative | 1,667 | $0.00 Strike: $9.20 | $0.00 |
DisclosureSEC source: 0001437749-25-025087 · rdgdoc.xml · derivative · entry 1 Tardugno Michael H · CIK 0001384550 · Director · Executive Chairman of Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,667 Underlying: Common Stock · 1,667 shares Expires 2035-08-04 F1 · derivative.exercise_price: Represents the closing price of Imunon, Inc. Common Stock on the date of the grant F2 · derivative.exercise_date: The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 20:17 UTC | Imunon, Inc. IMNN · Entity 8041 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001437749-25-008260 · rdgdoc.xml · derivative · entry 1 Tardugno Michael H · CIK 0001384550 · Director · Executive Chairman of Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2035-03-14 F1 · derivative.exercise_price: Represents the closing price of Imunon, Inc. Common Stock on the date of grant. F2 · derivative.exercise_date: The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant. Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 21:14 UTC | Imunon, Inc. IMNN · Entity 8041 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $0.83 | $0.00 |
DisclosureSEC source: 0001437749-24-037954 · rdgdoc.xml · derivative · entry 1 Tardugno Michael H · CIK 0001384550 · Director · Executive Chairman of Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2034-12-18 F1 · derivative.exercise_price: Represents the closing price of Imunon, Inc. Common Stock on the date of grant. F2 · derivative.exercise_date: The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant. Read SEC document |
| September 06, 2024 Filed Sep 10, 2024 20:47 UTC | Imunon, Inc. IMNN · Entity 8041 | GrantStock Option (Right to Buy) · Derivative | 82,926 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001437749-24-028875 · rdgdoc.xml · derivative · entry 1 Tardugno Michael H · CIK 0001384550 · Director · Executive Chairman of Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 394,759 Underlying: Common Stock · 82,926 shares Expires 2034-09-06 F1 · derivative.exercise_price: Represents the closing price of Imunon, Inc. Common Stock on the date of grant. F3 · shares: Option granted in lieu of cash payment increases. F2 · derivative.exercise_date: The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant. Read SEC document |
| August 15, 2024 Filed Aug 16, 2024 12:01 UTC | Imunon, Inc. IMNN · Entity 8041 | PurchaseImunon Common Stock | 25,000 | $1.03 | $25,750.00 |
DisclosureSEC source: 0001437749-24-027058 · rdgdoc.xml · nonDerivative · entry 1 Tardugno Michael H · CIK 0001384550 · Director · Executive Chairman of Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 353,346 F1 · shares: The Chairman purchased the stock on the open market. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 10:15 UTC | Imunon, Inc. IMNN · Entity 8041 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0001437749-24-020266 · rdgdoc.xml · derivative · entry 1 Tardugno Michael H · CIK 0001384550 · Director · Executive Chairman of Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 328,346 Underlying: Common Stock · 100,000 shares Expires 2034-06-12 F1 · derivative.exercise_price: Represents the closing price of Imunon, Inc. Common Stock on the date of grant. F2 · derivative.exercise_date: The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant. Read SEC document |
| March 15, 2024 Filed Mar 18, 2024 21:09 UTC | Imunon, Inc. IMNN · Entity 8041 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $0.86 | $0.00 |
DisclosureSEC source: 0001437749-24-008345 · rdgdoc.xml · derivative · entry 1 Tardugno Michael H · CIK 0001384550 · Director · Executive Chairman of Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 228,346 Underlying: Common Stock · 12,500 shares Expires 2034-03-15 F1 · derivative.exercise_price: Represents the closing price of Imunon, Inc. Common Stock on the date of grant. F2 · derivative.exercise_date: The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant. Read SEC document |
| March 17, 2023 Filed Mar 21, 2023 20:39 UTC | Imunon, Inc. IMNN · Entity 8041 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0001437749-23-007404 · rdgdoc.xml · derivative · entry 1 Tardugno Michael H · CIK 0001384550 · Director · Executive Chairman of Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,846 Underlying: Common Stock · 25,000 shares Expires 2033-03-17 F1 · derivative.exercise_price: Represents the closing price of Imunon, Inc. Common Stock on the date of grant. F2 · derivative.exercise_date: The options vest as follows: 1/3 on the date of grant; 1/3 on the on the one year anniversary of the date of grant; and 1/3 on the second year anniversary of the date of grant. Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 20:32 UTC | Imunon, Inc. CLSN · Entity 8041 | GrantOption to Purchase Celsion Common Stock · Derivative | 90,000 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001437749-22-015057 · rdgdoc.xml · derivative · entry 1 Tardugno Michael H · CIK 0001384550 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 303,068 Underlying: Celsion Corporation Common Stock · 90,000 shares Expires 2032-06-13 F1 · derivative.exercise_price: Represents the per share fair value of the Common Stock based on the closing price of a share of Celsion Corporation Common Stock on the date of the grant. F2 · derivative.exercise_date: The Options vest as follows: 1/3 on the date of the grant, 1/3 on the one year anniversary of the date of the grant, and 1/3 on the second year anniversary of the date of the grant. Read SEC document |
| April 12, 2022 Filed Apr 12, 2022 18:19 UTC | Imunon, Inc. CLSN · Entity 8041 | PurchaseCelsion Corporation Common Stock | 4,000 | $3.53 | $14,129.20 |
DisclosureSEC source: 0001437749-22-008740 · rdgdoc.xml · nonDerivative · entry 1 Tardugno Michael H · CIK 0001384550 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,513 F1 · shares: The shares were purchased on the open market. Read SEC document |
| March 04, 2022 Filed Mar 7, 2022 23:06 UTC | Imunon, Inc. CLSN · Entity 8041 | GrantOption to Purchase Celsion Common Stock · Derivative | 80,000 | $0.00 Strike: $4.60 | $0.00 |
DisclosureSEC source: 0001437749-22-005439 · rdgdoc.xml · derivative · entry 1 Tardugno Michael H · CIK 0001384550 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,068 Underlying: Celsion Corporation Common Stock · 80,000 shares Expires 2032-03-04 F1 · derivative.exercise_price: Represents the per share fair value of the Common Stock based on the closing price of a share of Celsion Corporation Common Stock on the date of the grant. F2 · derivative.exercise_date: The Options vest as follows: 1/3 on the date of the grant, 1/3 on the one year anniversary of the date of the grant, and 1/3 on the second year anniversary of the date of the grant. Read SEC document |
| March 19, 2021 Filed Mar 22, 2021 20:53 UTC | Imunon, Inc. CLSN · Entity 8041 | GrantOption to Purchase Celsion Corporation Common Stock · Derivative | 650,000 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0001437749-21-006773 · rdgdoc.xml · derivative · entry 1 Tardugno Michael H · CIK 0001384550 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,996,071 Underlying: Celsion Corporation Common Stock · 650,000 shares Expires 2031-03-19 F1 · derivative.exercise_price: Represents the closing price of Celsion Corporation Common Stock on the date of grant. F2 · derivative.exercise_date: The options vest as follows: 1/3 immediately, 1/3 on the first anniversary of the date of grant and 1/3 on the second year anniversary of the date of grant. Read SEC document |
| June 15, 2020 Filed Jun 16, 2020 21:09 UTC | Imunon, Inc. CLSN · Entity 8041 | GrantOption to Purchase Celsion Corporation Common Stock · Derivative | 850,000 | $0.00 Strike: $2.58 | $0.00 |
DisclosureSEC source: 0001437749-20-013254 · rdgdoc.xml · derivative · entry 3 Tardugno Michael H · CIK 0001384550 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,346,071 Underlying: Celsion Corporation Common Stock · 850,000 shares Expires 2028-05-15 F3 · derivative.exercise_price: The transaction reported herein reflects a one-time stock option repricing that became effective on June 15, 2020 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the settlement agreement as filed as Exhibit 10.2 on Form 8K dated June 16, 2020, the per share exercise price of the Employee Stock Option (right to buy) has been amended to increase such per share exercise price from $2.22 to $2.58. There have been no other changes to the terms of the Employee Stock Option (right to buy). F3 · shares: The transaction reported herein reflects a one-time stock option repricing that became effective on June 15, 2020 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the settlement agreement as filed as Exhibit 10.2 on Form 8K dated June 16, 2020, the per share exercise price of the Employee Stock Option (right to buy) has been amended to increase such per share exercise price from $2.22 to $2.58. There have been no other changes to the terms of the Employee Stock Option (right to buy). F3 · derivative.underlying_shares: The transaction reported herein reflects a one-time stock option repricing that became effective on June 15, 2020 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the settlement agreement as filed as Exhibit 10.2 on Form 8K dated June 16, 2020, the per share exercise price of the Employee Stock Option (right to buy) has been amended to increase such per share exercise price from $2.22 to $2.58. There have been no other changes to the terms of the Employee Stock Option (right to buy). Read SEC document |
| June 15, 2020 Filed Jun 16, 2020 21:09 UTC | Imunon, Inc. CLSN · Entity 8041 | Disposition to issuerOption to Purchase Celsion Corporation Common Stock · Derivative | 850,000 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0001437749-20-013254 · rdgdoc.xml · derivative · entry 2 Tardugno Michael H · CIK 0001384550 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 510,071 Underlying: Celsion Corporation Common Stock · 850,000 shares Expires 2028-05-15 F3 · derivative.exercise_price: The transaction reported herein reflects a one-time stock option repricing that became effective on June 15, 2020 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the settlement agreement as filed as Exhibit 10.2 on Form 8K dated June 16, 2020, the per share exercise price of the Employee Stock Option (right to buy) has been amended to increase such per share exercise price from $2.22 to $2.58. There have been no other changes to the terms of the Employee Stock Option (right to buy). F3 · shares: The transaction reported herein reflects a one-time stock option repricing that became effective on June 15, 2020 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the settlement agreement as filed as Exhibit 10.2 on Form 8K dated June 16, 2020, the per share exercise price of the Employee Stock Option (right to buy) has been amended to increase such per share exercise price from $2.22 to $2.58. There have been no other changes to the terms of the Employee Stock Option (right to buy). F3 · derivative.underlying_shares: The transaction reported herein reflects a one-time stock option repricing that became effective on June 15, 2020 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the settlement agreement as filed as Exhibit 10.2 on Form 8K dated June 16, 2020, the per share exercise price of the Employee Stock Option (right to buy) has been amended to increase such per share exercise price from $2.22 to $2.58. There have been no other changes to the terms of the Employee Stock Option (right to buy). Read SEC document |
| June 15, 2020 Filed Jun 16, 2020 21:09 UTC | Imunon, Inc. CLSN · Entity 8041 | GrantOption to Purchase Celsion Corporation Common Stock · Derivative | 135,000 | $0.00 Strike: $3.66 | $0.00 |
DisclosureSEC source: 0001437749-20-013254 · rdgdoc.xml · derivative · entry 1 Tardugno Michael H · CIK 0001384550 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,346,071 Underlying: Celsion Corporation Common Stock · 135,000 shares Expires 2030-06-15 F1 · derivative.exercise_price: Represents the closing price of Celsion Corporation Common Stock on the date of grant. F2 · derivative.exercise_date: The options vest as follows: 1/3 on the one year anniversary of the date of grant; 1/3 on the second year anniversary of the date of grant; and 1/3 on the third year anniversary of the date of grant. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 22:01 UTC | Imunon, Inc. CLSN · Entity 8041 | GrantCelsion Corporation Common Stock | 155,000 | $1.16 | $179,800.00 |
DisclosureSEC source: 0001437749-20-003785 · rdgdoc.xml · nonDerivative · entry 1 Tardugno Michael H · CIK 0001384550 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,700 F1 · shares: The Filer received Celsion Common Stock as part of their incentive compensation. Read SEC document |
| October 03, 2019 Filed Oct 7, 2019 20:38 UTC | Imunon, Inc. CLSN · Entity 8041 | GrantOption to Purchase Celsion Corporation Common Stock · Derivative | 65,000 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001437749-19-019787 · rdgdoc.xml · derivative · entry 1 Tardugno Michael H · CIK 0001384550 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,211,071 Underlying: Celsion Corporation Common Stock · 65,000 shares Expires 2029-10-03 F1 · derivative.exercise_price: Represents the closing price of Celsion Corporation Common Stock on the date of grant. F2 · derivative.exercise_date: The options vest as follows: 1/3 on the one year anniversary of the date of grant; 1/3 on the second year anniversary of the date of grant; and 1/3 on the third year anniversary of the date of grant. Read SEC document |
| May 16, 2019 Filed May 16, 2019 19:50 UTC | Imunon, Inc. CLSN · Entity 8041 | PurchaseCelssion Corporation Common Stock | 5,000 | $2.16 | $10,810.00 |
DisclosureSEC source: 0001437749-19-010232 · rdgdoc.xml · nonDerivative · entry 1 Tardugno Michael H · CIK 0001384550 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,700 F1 · shares: The shares were purchased on the open market. Read SEC document |
| May 14, 2019 Filed May 15, 2019 21:40 UTC | Imunon, Inc. CLSN · Entity 8041 | GrantOption to Purchase Celsion Corporation Common Stock · Derivative | 50,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001437749-19-010127 · rdgdoc.xml · derivative · entry 1 Tardugno Michael H · CIK 0001384550 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,146,071 Underlying: Celsion Corporation Common Stock · 50,000 shares Expires 2029-05-14 F1 · derivative.exercise_price: Represents the closing price of Celsion Corporation Common Stock on the date of grant. F2 · derivative.exercise_date: The options vest as follows: 1/3 on the one year anniversary of the date of grant; 1/3 on the second year anniversary of the date of grant; and 1/3 on the third year anniversary of the date of grant. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 21:55 UTC | Imunon, Inc. CLSN · Entity 8041 | GrantOption to Purchase Celsion Corporation Common Stock · Derivative | 50,000 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001437749-19-003087 · rdgdoc.xml · derivative · entry 1 Tardugno Michael H · CIK 0001384550 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,096,071 Underlying: Celsion Corporation Common Stock · 50,000 shares Expires 2029-02-19 F1 · derivative.exercise_price: Represents the closing price of Celsion Corporation Common Stock on the date of grant. F2 · derivative.exercise_date: The options vest as follows: 1/3 on the one year anniversary of the date of grant; 1/3 on the second year anniversary of the date of grant; and 1/3 on the third year anniversary of the date of grant. Read SEC document |
| October 29, 2018 Filed Oct 30, 2018 12:38 UTC | Imunon, Inc. CLSN · Entity 8041 | PurchaseCelsion Corporation Common Stock | 7,500 | $2.06 | $15,483.75 |
DisclosureSEC source: 0001437749-18-019001 · rdgdoc.xml · nonDerivative · entry 1 Tardugno Michael H · CIK 0001384550 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,700 F1 · shares: The shares were purchased on the open market. Read SEC document |
| May 15, 2018 Filed May 16, 2018 21:12 UTC | Imunon, Inc. CLSN · Entity 8041 | GrantOption to Purchase Celsion Corporation Common Stock · Derivative | 850,000 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0001437749-18-010165 · rdgdoc.xml · derivative · entry 1 Tardugno Michael H · CIK 0001384550 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,046,071 Underlying: Celsion Corporation Common Stock · 850,000 shares Expires 2028-05-15 F1 · derivative.exercise_price: Represents the closing stock price on the option grant date (February 12, 2018) which was subject to the approval of the Celsion Corporation 2018 Stock Incentive Plan at the Annual Meeting of Stockholders held on May 15, 2018. F2 · derivative.exercise_date: The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant. Read SEC document |
| April 09, 2018 Filed Apr 9, 2018 17:14 UTC | Imunon, Inc. CLSN · Entity 8041 | PurchaseCelsion Corporation Common Stock | 2,500 | $2.30 | $5,750.00 |
DisclosureSEC source: 0001437749-18-006524 · rdgdoc.xml · nonDerivative · entry 1 Tardugno Michael H · CIK 0001384550 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,200 F1 · shares: The shares were purchased on the open market. Read SEC document |
| March 05, 2018 Filed Mar 5, 2018 16:24 UTC | Imunon, Inc. CLSN · Entity 8041 | PurchaseCelsion Corporation Common Stock | 7,500 | $2.38 | $17,839.50 |
DisclosureSEC source: 0001437749-18-003864 · rdgdoc.xml · nonDerivative · entry 1 Tardugno Michael H · CIK 0001384550 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,700 F1 · shares: The shares were purchased on the open market. Read SEC document |
| May 30, 2017 Filed Jun 1, 2017 20:37 UTC | Imunon, Inc. CLSN · Entity 8041 | GrantOption to Purchase Celsion Corporation Common Stock · Derivative | 176,429 | $0.00 Strike: $2.69 | $0.00 |
DisclosureSEC source: 0001437749-17-010467 · rdgdoc.xml · derivative · entry 1 Tardugno Michael H · CIK 0001384550 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,429 Underlying: Celsion Corporation Common Stock · 176,429 shares Expires 2027-05-30 F1 · derivative.exercise_price: Represents the closing price of Celsion Corporation Common Stock on the date of grant. F2 · derivative.exercise_date: The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant. Read SEC document |
| October 07, 2016 Filed Oct 11, 2016 13:13 UTC | Imunon, Inc. CLSN · Entity 8041 | PurchaseCelsion Corporation Common Stock | 10,000 | $1.14 | $11,400.00 |
DisclosureSEC source: 0001437749-16-039653 · rdgdoc.xml · nonDerivative · entry 1 Tardugno Michael H · CIK 0001384550 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,021 F1 · shares: The Chairman, President and Chief Executive Officer purchased the shares on the open market Read SEC document |
| September 06, 2016 Filed Sep 8, 2016 20:39 UTC | Imunon, Inc. CLSN · Entity 8041 | GrantOption to Purchase Celsion Corporation Common Stock · Derivative | 125,000 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0001437749-16-038502 · rdgdoc.xml · derivative · entry 1 Tardugno Michael H · CIK 0001384550 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 923,885 Underlying: Celsion Corporation Common Stock · 125,000 shares Expires 2026-09-06 F1 · derivative.exercise_price: Represents the closing price of Celsion Corporation Common Stock on the date of grant. F2 · derivative.exercise_date: The option vests on the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.